Neurogene Q3 net loss widens on higher R&D and G&A costs
NGNE•Neurogene’s third-quarter net loss widened to $29.02 million as research and development and general and administrative costs increased. The company ended the quarter with $359.7 million in cash, which it expects to fund operations into the first quarter of 2029.
1. Quarterly results
Neurogene reported a third-quarter net loss of $29.02 million, with operating expenses totaling $32.38 million. Higher research and development costs reflected increased spending on its NGN-401 clinical trial and manufacturing activities, partly offset by lower spending on its CLN5 Batten disease program. General and administrative costs rose with higher stock-based compensation, headcount, pre-commercial activities and professional fees.
2. Cash and outlook
Neurogene ended the quarter with $359.7 million in cash and expects the funds to support operations into the first quarter of 2029. The company expects topline data from its Embolden trial in the second half of 2027 and remains on track to complete PPQ runs for a BLA submission by year-end 2026.
